469 476
[13]
Sjodahl G, Lauss M, Lovgren K, et al. A molecular taxonomy for urothelial carcinoma. Clin Cancer Res 2012;18:3377–86.
[14]
Patschan O, Sjodahl G, Chebil G, et al. A molecular pathologic framework for risk stratification of stage T1 urothelial carcinoma. Eur Urol 2015;68:824–32.[15]
Hedegaard J, Lamy P, Nordentoft I, et al. Comprehensive transcrip- tional analysis of early-stage urothelial carcinoma. Cancer Cell 2016;30:27–42.[16]
Dyrskjot L, Zieger K, Real FX, et al. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin Cancer Res 2007;13:3545–51.[17]
Dyrskjot L, Reinert T, Novoradovsky A, et al. Analysis of molecular intra-patient variation and delineation of a prognostic 12-gene signature in non-muscle invasive bladder cancer; technology trans- fer from microarrays to PCR. Br J Cancer 2012;107:1392–8.[18]
Kluth LA, Black PC, Bochner BH, et al. Prognostic and prediction tools in bladder cancer: a comprehensive review of the literature. Eur Urol 2015;68:238–53.[19]
van Rhijn BW, Vis AN, van der Kwast TH, et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 2003;21:1912–21.
[20]
van Rhijn BW, Zuiverloon TC, Vis AN, et al. Molecular grade (FGFR3/ MIB-1) and EORTC risk scores are predictive in primary non-mus- cle-invasive bladder cancer. Eur Urol 2010;58:433–41.[21]
Burger M, van der Aa MN, van Oers JM, et al. Prediction of progres- sion of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. Eur Urol 2008;54:835–43.[22]
Hernandez S, Lopez-Knowles E, Lloreta J, et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 2006;24:3664–71.[23]
Fristrup N, Birkenkamp-Demtroder K, Reinert T, et al. Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer. Am J Pathol 2013;182:339–49.
[24]
Fristrup N, Ulhoi BP, Birkenkamp-Demtroder K, et al. Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein mar- kers for progression in non-muscle invasive bladder cancer. Am J Pathol 2012;180:1824–34.
[25]
Jensen JB, Munksgaard PP, Sorensen CM, et al. High expression of karyopherin-alpha2 defines poor prognosis in non-muscle-invasive bladder cancer and in patients with invasive bladder cancer under- going radical cystectomy. Eur Urol 2011;59:841–8.
[26]
Hoglund M. On the origin of syn- and metachronous urothelial carcinomas. Eur Urol 2007;51:1185–93.[27]
Nordentoft I, Lamy P, Birkenkamp-Demtroder K, et al. Mutational context and diverse clonal development in early and late bladder cancer. Cell Rep 2014;7:1649–63.
[28]
van Tilborg AA, de Vries A, de Bont M, et al. Molecular evolution of multiple recurrent cancers of the bladder. Hum Mol Genet 2000;9:2973–80.
[29]
Hafner C, Knuechel R, Stoehr R, Hartmann A. Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies. Int J Cancer 2002;101:1–6.[30]
Birkenkamp-Demtroder K, Nordentoft I, Christensen E, et al. Geno- mic alterations in liquid biopsies from patients with bladder cancer. Eur Urol 2016;70:75–82.E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 4 6 1 – 4 6 9
469